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Connections between vascular calcification and progression
of chronic kidney disease: Therapeutic alternatives. We have
shown that renal injury and chronic kidney disease (CKD) di-
rectly inhibit skeletal anabolism, and that stimulation of bone
formation decreases the serum phosphate. Most recently, these
observations were rediscovered in low-density lipoprotein re-
ceptor null mice fed high-fat/cholesterol diets, a model of the
metabolic syndrome (hypertension, obesity, dyslipidemia, and
insulin resistance). We had demonstrated that these mice have
vascular calcification (VC) of both the intimal atherosclerotic
type and medial type.We have shown that VC is worsened
by CKD and ameliorated by bone morphogenetic protein -7
(BMP-7). The finding that high-fat-fed low-density lipoprotein
receptor null animals without CKD have hyperphosphatemia
led us to examine the skeletons of these mice. We found sig-
nificant reductions in bone formation rates, associated with in-
creased VC and superimposing CKD results in the adynamic
bone disorder (ABD), while VC was worsened and hyper-
phosphatemia persisted. A pathological link between abnormal
bone mineralization and VC through the serum phosphorus was
demonstrated by the partial effectiveness of directly reducing
the serum phosphate by a phosphate binder that had no skeletal
action. BMP-7 treatment corrected the ABD and corrected hy-
perphosphatemia, compatible with BMP-7–driven stimulation
of skeletal phosphate deposition reducing plasma phosphate
and thereby removing a major stimulus to VC.
Thus, in the metabolic syndrome with CKD, a reduction in
bone-forming potential of osteogenic cells leads to ABD pro-
ducing hyperphosphatemia and VC, processes ameliorated by
the skeletal anabolic agent BMP-7, in part through increased
bone formation and skeletal deposition of phosphate, and in
part through direct actions on vascular smooth muscle cells.
We have demonstrated that the processes leading to vascular
calcification begin with even mild levels of renal injury before
demonstrable hyperphosphatemia, and they are preventable
and treatable. Therefore, early intervention in CKD is war-
ranted and may affect mortality of the disease.
Progression of chronic kidney disease (CKD) is gen-
erally considered in terms of progressive loss of kidney
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function until end-stage kidney failure occurs and renal
replacement therapy begins. However, CKD is a systemic
disease, and it is also a fatal one. Therefore, it is useful to
consider mechanisms of how kidney failure progresses to
death despite replacement of the detoxifying actions of
the kidney by dialysis and transplantation. Indeed, more
patients with CKD die before reaching need for dialysis
than accrue to modalities of renal replacement therapy
[1]. Cardiovascular mortality in patients with CKD is ex-
tremely high [17, 14].Conventional risk factors character-
istic of the metabolic syndrome [2] such as hypertension,
dyslipidemia, insulin resistance, and overt diabetes mel-
litus are highly prevalent in CKD, but other risk factors
with additive effects that are more specific to the ure-
mic milieu have also been identified [13]. One such is
the presence of vascular calcification (VC) [89], a form
of heterotopic mineralization that is predictive of cardio-
vascular (CV)mortality [90, 91] and is both common and
severe in CKD [92].
The pathogenesis of VC in CKD is unknown, but hy-
perphosphatemia is an important risk factor for both VC
and CV mortality [88, 93]. VC and CV mortality are also
associated with other abnormalities of calcium and phos-
phate homeostasis, including raised calcium concentra-
tions, a raised calcium and phosphate ion product, and
hyperparathyroidism [92, 88], and these findings suggest
a link with renal osteodystrophy (ROD).
ROD is virtually ubiquitous in CKD, characterized by
a spectrum of histological abnormalities of bone that con-
tribute to the biochemical abnormalities discussed above
[87]. At one end of the spectrum, osteitis fibrosa is a high-
turnover state driven by secondary hyperparathyroidism,
characterized by poorly differentiated osteoblasts pre-
cursors manifesting a fibroblastic phenotype, and stimu-
lating increased osteoclastic activity. This results in net
bone resorption, fibrosis of the bone marrow space, and
release of calcium and phosphate into the extracellular
fluid. At the other end of the spectrum, adynamic bone
disease (ABD) is characterized by quiescent osteoblasts
and osteoclasts with markedly reduced bone turnover.
In this situation, reduction of the rapidly diffusible ion
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pool associated with normal mineralization reduces the
body’s ability to buffer extracellular calcium and phos-
phate ion concentrations, causing increased postprandial
fluctuation as a result. Thus, both forms of ROD cause ab-
normalities in bone biochemistry that are associated with
VC, and it is possible to hypothesize a causative patho-
logical link between ROD, VC, and mortality in CKD.
We have developed an animal model of VC wors-
ened by CKD [18]. The model is partial renal abla-
tion in the low-density lipoprotein receptor–deficient
(LDLR−/−) mouse fed high-fat/cholesterol diets. This
model resembles the clinical situation of CKD compli-
cating the metabolic syndrome, because the mice have
obesity, hypertension, insulin resistance, and early type
II diabetes. In these animals, CKD caused intensification
of VC, which was prevented by treatment with bone mor-
phogenetic protein-7 (BMP-7) [18].
In the study presented herein, the aims were to examine
the mechanisms of VC by characterizing its relationship
to ROD in CKD superimposed on the metabolic syn-
drome. We found that CKD induced ABD in this model
despite the presence of hyperparathyroidism. Further-
more, CKD intensified hyperphosphatemia, which was
already present in the high-fat/cholesterol-fed animals.
Treatment with BMP-7 reversed ABD, corrected hyper-
phosphatemia, and prevented VC. The role of hyper-
phosphatemia in VC was investigated by using calcium
carbonate as a dietary supplement to control hyper-
phosphatemia. Calcium carbonate corrected hyperphos-
phatemia, may have increased the ABD, and reduced VC.
Thus, a basic mechanism of VC may reside in the control
of the serum phosphate in CKD, and the skeleton and the
vasculature may be linked by the serum phosphate.
MATERIALS AND METHODS
Animals, diets, induction of CKD, and treatment protocol
LDLR−/− mice of both sexes in a C57/BL6 back-
ground were weaned at 3 weeks to a standard chow diet.
At 10 weeks, animals either continued chow or started a
high-cholesterol diet (0.15% diet containing 42% calories
as fat). At 12 weeks, CKD was induced in some animals
by the procedure previously described by Gagnon [36].
After the second surgical/sham procedure, 14-week-old
animals were randomized into the experimental groups.
The BMP-7 dose was chosen as the low dose that was
previously shown to reverse VC in these animals [18].
Measurements of parathyroid hormone
and serum chemistry
Blood samples were obtained at 4 weeks of CKD
by capillary tube aspiration of the saphenous vein, and
with a different procedure (intracardiac puncture) at
the time the mice were killed(14 weeks of CKD), and
transferred to heparinized tubes. After centrifugation
(400× g for 5 min), plasma was removed, aliquoted,
and frozen at −80◦C. Intact parathyroid (PTH) levels
(performed only when mice were killed because of the
volume of blood required) were measured by two-site im-
munoradiometric assay with a commercially available kit
(Immunotopics, San Clemente, CA, USA). Blood urea
nitrogen (BUN), serum cholesterol, glucose, calcium, and
phosphorus were measured with commercially available
kits (Roche Diagnostics Corporation, Indianapolis, IN,
USA).
Chemical calcification quantitation of aortic tissue and
histological analysis
Calcium was eluted from desiccated, crushed tissue in
10% Formic acid (10:1 vol/wt) for 24 hours at 4◦C. Assay
of eluate calcium content was determined bya Cresolph-
thalein complexone method (Calcium Kit; Sigma, St.
Louis, MO, USA), according to manufacturer’s instruc-
tions and values corrected for dry tissue weight [37].
For histology, we fixed resected specimens in formalin
and then divided as previously reported [18]. The heart
and proximal aorta up to and including the arch were sep-
arated from the descending aorta and bisected sagittally
through the aortic outflow tract. Five-micrometer-thick
slices were stained with Alizarin red and von Kossa.
Bone histology and histomorphometry
Bone histomorphometry including the dynamics pa-
rameter of bone formation rate was determined 14 weeks
after nephrectomy by double fluorescent labeling with
methods we have previously reported. Primary, derived,
and kinetic measures of bone remodeling were calculated
and reported per the guidelines of the American Society
of Bone and Mineral Research [38].
Calculations
Statistical analyses were performed with analysis of
variance. Differences between groups were assessed post
hoc with Dunnett’s multiple range test and considered
significant when P < 0.05. Data are expressed as mean ±
standard deviation.
RESULTS
Evaluation of renal insufficiency
BUN levels were used to assess changes in renal func-
tion in the various groups of mice. Renal function was
stable during the 14-week treatment periods as we have
previously demonstrated in each of the individual groups.
Electrocautery removes kidney tissue-fixing renal func-
tion, and murine renal ablation, as compared with ro-
dent 5/6 nephrectomy, does not progress to end-stage
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CKD [18]. The BUN levels in sham-operated wild-type
mice were 25 ± 10 mg/dL, and in the sham-operated
LDLR−/− groups, they averaged 34 ± 17 mg/dL, demon-
strating early renal insufficiency. The level of CKD in-
duced by electrocautery and nephrectomy in the studies
reported here could be regarded as moderate to severe,
because BUN levels were approximately two to three
times normal. In CKD high-fat/cholesterol-fed mice (N =
19), the mean BUN was 81 ± 20mg/dL (P < 0.05) com-
pared with the sham chow or sham fat groups. BUN levels
in animals with CKD treated with BMP-7 (N = 12) were
105 ± 11 mg/dL and not significantly different from an-
imals with CKD that had not received treatment. They
were also stable from week 14 to week 28 when they were
killed. The difference in BUN levels represents slightly
more severe renal ablation in the CKD treated with BMP-
7 group.
Intact PTH levels in wild-type mice eating a regu-
lar chow diet averaged 19 ± 20 pg/mL. PTH levels
in the LDLR−/− mice were higher, 46 ± 20 pg/mL.
There were no differences in the levels of immunore-
active PTH between the sham-operated LDLR−/− an-
imals fed a chow diet or a high-fat/cholesterol diet. The
CKD animals on a high-fat/cholesterol diet developed
secondary hyperparathyroidism with mean PTH levels
of 174 ± 100 pg/mL. The CKD animals on a high-
fat/cholesterol diet given exogenous BMP-7 developed
mean PTH levels of 162 ± 200 pg/mL, not unlike the
vehicle-treated group. Calcium carbonate supplementa-
tion normalized the PTH levels in CKD. Cholesterol lev-
els were high in chow-fed LDLR−/− mice, and they were
further massively increased by high-fat feeding. There
were no differences in plasma cholesterol among the
high-fat/cholesterol-fed groups. The LDLR−/− sham-
operated mice were borderline hyperglycemic in the fast-
ing state, thus insulin resistant. CKD tended to diminish
the blood sugar. Glycemia was not affected by BMP-7.
The LDLR−/− mice fed high-fat/cholesterol and sub-
jected to sham surgery gained significantly more weight
than chow-fed animals and became obese. Addition of
either BMP-7 or CKD reversed the tendency to excess
weight gain. Food consumption and weight gain were the
same for each of the four CKD groups, which were less
than the sham-operated groups.
The serum phosphorus, calcium, and calcium phospho-
rus products in LDLR-deficient mice that were fed chow
exhibited a tendency to have elevated serum phosphate
levels compared with wild-type animals, which developed
into frank hyperphosphatemia upon high-fat feeding. The
CKD animals fed a high-fat/cholesterol diet developed
significant hyperphosphatemia over the 14-week period,
slightly greater than the sham high-fat/cholesterol-fed an-
imals. The hyperphosphatemia was reversed by BMP-
7 and calcium carbonate to the level of the LDLR−/−
chow-fed, sham-operated animals. There were no signifi-
cant differences in the calcium levels between the groups,
except that the calcium carbonate– supplemented diet
CKD group was hypocalcemic. The product of calcium
and phosphate mirrored the phosphate results with the
sham and CKD high- fat/cholesterol-fed animals having
elevated levels that were reduced to sham chow-fed lev-
els by BMP-7 therapy. The CKD calcium carbonate group
had the lowest calcium and phosphate product because
of the hypocalcemia.
Effect of high-fat feeding, CKD, and treatment with
BMP-7 on bone histology and histomorphometry
The LDLR−/− chow-fed mice exhibited prominent
trabecular osteoblast surfaces and normal osteoclast
surfaces. High fat feeding the LDLR−/− mice was asso-
ciated with a reduction in trabecular osteoblast surfaces,
and this observation was heightened in the LDLR−/−
high-fat CKD animals. The CKD high-fat-fed animals
treated with vehicle did not exhibit any of the features
of osteitis fibrosa associated with their secondary hy-
perparathyroidism, which we have previously shown in
wild-type mice with milder CKD than produced here
and with lower PTH levels [26]. The CKD high-fat-fed
animals treated with BMP-7 exhibited increased trabec-
ular number and trabecular osteoblast surfaces that were
normal. The CKD high-fat-fed animals supplemented
with calcium carbonate were indistinguishable from the
CKD high-fat-fed animals with loss of osteoblast-covered
trabecular surfaces. The CKD high-fat-fed animals sup-
plemented with calcium carbonate and BMP-7 treated
were indistinguishable from the CKD high-fat-fed ani-
mals treated with BMP-7.
There were no differences in bone volume, trabecu-
lar number, and trabecular separation among the vari-
ous groups despite a tendency for the high-fat-fed CKD
vehicle-treated group to be osteopenic. The animals with
CKD fed high fat and treated with vehicle had increased
osteoid volume compared with chow-fed, sham-operated
LDLR−/− mice. Osteoid thickness tended to be de-
creased in LDLR−/− animals compared with wild type,
and CKD tended to increase osteoid thickness, but these
changes were not significant. However, the expected find-
ings of high-turnover osteodystrophy were not observed
in this group. Instead, the features of the ABD were ob-
served. Osteoblast numbers and perimeters were signif-
icantly reduced in CKD high-fat-fed, vehicle-treated an-
imals compared with chow-fed, sham-operated animals
(Fig. 1D and E), as were mineralizing surfaces (Fig. 2A)
and bone formation rates (Fig. 2B). Bone formation
rates were also significantly reduced in the sham- op-
erated LDLR−/− high-fat-fed, vehicle-treated animals
(Fig. 2B), confirming the tendency for decreased os-
teoblast number and perimeter shown in Figures 1D
and E compared with the sham chow LDLR−/− group.
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Fig. 1. Bone volume, osteoid volume, osteoclast number, osteoblast perimeter, and osteoblast number in metaphyseal trabeculae. There were no
significant changes in bone volume between groups (A), although there was an osteopenic tendency in the LDLR−/− high-fat-fed CKD group.
There was a significant hyperosteoidosis produced in the CKD high-fat-fed group (B), possibly related to the secondary hyperparathyroidism as
expected (∗P < 0.05 compared with the sham group). There were no differences in osteoclast numbers between the groups (C). Osteoblast perimeter
(D) and number (E) were significantly reduced by CKD in the LDLR−/− high-fat-fed animals, and BMP-7 therapy restored osteoblast surfaces
and number to normal when compared with the LDLR−/− sham chow-fed animals or with wild-type chow-fed animals. (∗P < 0.05 compared with
sham chow-fed LDLR−/− animals). Values represent mean ± standard deviation. Reprinted from Davies et al, J Am Soc Nephrol 16:917–928,
2005, with permission from the American Society of Nephrology.
Osteoblast numbers and perimeter, along with bone for-
mation rates, tended to be higher in LDLR−/− chow-fed
animals than wild-type controls fed chow (Figs. 1D and
E, Fig. 2B).
The adjusted apposition rates were significantly de-
pressed in both the LDLR−/− high-fat-fed animals and
the LDLR−/− high-fat-fed CKD vehicle-treated groups
(Fig. 2C). Thus, the histomorphometry in the LDLR−/−
high-fat animals was consistent with ABD worsened by
CKD despite high PTH levels. The LDLR−/− high-fat-
fed animals had significant reductions in bone formation
rates (Fig. 2B) and adjusted apposition rates consis-
tent with their exhibited tendency to reduced osteoblast
perimeter (Fig. 1D) and number (Fig. 1E) when com-
pared with LDLR−/− chow-fed animals.
Treatment with BMP-7 in the CKD animals with ABD
resulted in a normalization of the osteoblast number
and perimeter (Fig. 1D, E), an increase in the miner-
alizing surfaces (Fig. 2A), and a normalization of the
bone formation and adjusted apposition rates (Fig. 2B
and C).
Supplementation of the high-fat/cholesterol diet with
calcium carbonate in CKD animals did not alter the os-
teoblast surface parameters (Fig. 2D, E), bone formation
rates (Fig. 2B), or adjusted apposition rates (Fig. 2C).
Thus, the calcium carbonate supplementation had no ef-
fect on ABD of the LDLR−/− high-fat-fed animals with
CKD. Treatment with BMP-7 eliminated ABD in calcium
carbonate–supplemented high-fat/cholesterol-fed CKD
animals by increasing osteoblast number, bone forma-
tion rates, and the adjusted apposition rate (Figs. 1D, E
and Figs. 2B, C).
Effects of CKD and treatment with BMP- 7 on aortic
calcium content
High-fat feeding tended to increase aortic calcium lev-
els twofold, and CKD plus high-fat feeding increased
it more than fourfold (Fig. 3A). BMP-7 therapy re-
duced aortic calcium to levels observed in the sham-
operated, chow-fed LDLR−/− mice. Calcium carbonate
supplementation also decreased aortic calcium levels but
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Fig. 2. Mineralizing surfaces, bone formation rates, and adjusted apposition rates. Mineralizing surfaces (A) were significantly decreased in the CKD
high-fat-fed animals. Despite the tendency for osteoblast number and perimeter to be increased in LDLR−/− chow-fed sham animals compared
with wild-type animals (Fig. 4.), the mineralizing surfaces were slightly lower and further decreased by high-fat feeding. The bone formation rates
(B) were significantly decreased by high-fat feeding in both the sham and CKD groups and returned to normal by BMP-7 therapy. Reprinted from
Davies et al, J Am Soc Nephrol 16:917–928, 2005, with permission from the American Society of Nephrology.
not to levels observed in the sham-operated, chow-fed
LDLR−/− mice. We have previously characterized the
aortic lesions causing changes in calcium levels [18], and
the observations made in this study confirmed our previ-
ous data. High-fat/cholesterol feeding of sham-operated
LDLR−/− animals induced punctate calcium deposits
in proximal aortic neointimal plaques and in the aortic
media. These lesions were worsened by ablative CKD
both in the neointima and the medial wall, accounting
for the effect of CKD on aortic calcium levels. Cal-
cium carbonate supplementation decreased the preva-
lence of calcifications, especially in the media, but did not
eliminate them. There were calcifications remaining in
each of the calcium carbonate–supplemented CKD high-
fat/cholesterol-fed animals. Treatment of the calcium
carbonate–supplemented CKD high-fat/cholesterol-fed
animals with BMP-7 resulted in complete disappearance
of visible calcification lesions similar to the effect of BMP-
7 in CKD high-fat/cholesterol-fed animals we previously
reported [18].
To further analyze the apparent inverse relationship
between skeletal modeling and VC, we performed a re-
gression analysis between the adjusted apposition rate
(the estimate of the number of skeletal modeling units)
and aortic calcium levels (Fig. 3B). There was a significant
inverse multifactorial relationship between aortic cal-
cium levels and adjusted bone apposition rates in sham-
operated, chow-fed animals, sham-operated, high-fat-fed
animals, and CKD high-fat-fed animals.
DISCUSSION
We have previously demonstrated that renal injury di-
rectly impairs skeletal anabolism leading to decreased
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Fig. 3. (A) Aortic calcium levels in the vari-
ous animal groups. (B) Relationship between
adjusted bone apposition rates and aortic cal-
cium content in the three groups of animals.
bone formation, in agreement with results shown here
[25]. The effect of decreased bone formation is loss of
capacity in the exchangeable phosphate pool and larger-
than-normal excursions of the plasma phosphorus dur-
ing loading of the vascular compartment as with meals.
These excursions of plasma phosphorus are direct stimuli
to PTH secretion, so early hyperparathyroidism in CKD
is an adaptation to decreased bone formation. The prob-
lem is, of course, that it becomes maladaptive, because it
leads to excess bone resorption over formation and con-
tributes to sustained hyperphosphatemia as excretory ca-
pacity is lost. Thus, loss of bone formation is a stimulus
to hyperphosphatemia that may not be perceived in a
sustained elevation of the serum phosphate.
The studies reported here demonstrate that LDLR−/−
mice fed high-fat/cholesterol diets, an animal model of
the human metabolic syndrome, have significant reduc-
tions in skeletal matrix production measured as the ad-
justed apposition rate in the distal femoral metaphyses.
Bone formation rates were depressed, and tendencies for
mineralizing surfaces, osteoblast number, and osteoblast
perimeter to be reduced compared with LDLR chow-fed
animals were observed. When ablative CKD was super-
imposed, these tendencies became significant reductions,
and the hallmarks of ABD of CKD were fulfilled. A log-
ical interpretation is that a progressive loss of skeletal
anabolism was observed, going from LDLR−/− chow
fed to LDLR−/− high- fat fed to LDLR−/− high-fat fed
+ CKD without major changes in the osteoclast com-
partment, the latter another hallmark of the ABD of
renal failure. The surprising observation here was the re-
duction in bone formation rates stimulated by high-fat
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feeding in the LDLR−/− animals and the lack of re-
sponse to hyperparathyroidism when CKD was induced.
The reduction in adjusted apposition rates induced by
high-fat/cholesterol feeding correlated well with the os-
teoblast surfaces of metaphyseal trabeculae, which were
increased in LDLR−/− mice fed chow compared with
wild- type animals and decreased by high-fat feeding.
Thus, in the skeleton, the genetic induction of LDLR de-
ficiency was initially adapted for by increasing osteoblast
number, but high-fat/cholesterol feeding overcame this
adaptation, resulting in decreased osteogenic cells and
adjusted apposition rates in vivo.
The studies reported here and our previous studies
demonstrate that renal injury and CKD directly impair
skeletal anabolism measured as bone formation rate. This
impairs exit of phosphorus from the blood compartment
into the exchangeable phosphorus pool, producing a hy-
perphosphatemic stimulus associated with meals. This, in
turns, stimulates secretion of PTH. Thus, secondary hy-
perparathyroidism is an adaptation to the loss of skele-
tal anabolism, perhaps designed to maintain phosphate
homeostasis. When the adaptation’s effect is blocked, as
in diabetes, the outcome is ABD as CKD progresses. As
CKD progresses, hyperphosphatemia becomes apparent,
and a component previously unrecognized is due to ab-
normal skeletal remodeling.
Hyperphosphatemia is a direct stimulus to a phe-
notypic change in vascular smooth muscle cells that
results in the mineralization of the elastic lamina pro-
ducing tunica media calcification observed in CKD. This
contributes to vascular stiffness, increased pulse-wave ve-
locity, and pulse-wave pressures that lead to cardiac dis-
ease and mortality. Thus, there is a direct link between
the kidney and the skeleton and, in turn, between the
skeleton and the vasculature, the latter mediated by the
serum phosphorus, which progresses toward causing car-
diovascular mortality as CKD progresses.
In our study, two groups of animals had high values of
serum phosphate and calcium phosphorus products, the
LDLR−/− animals fed high-fat/cholesterol and the an-
imals with CKD fed high-fat/cholesterol. Both of these
groups had the histomorphometric features of the ABD,
and correction of the ABD was associated with reduction
of the serum phosphorus during BMP-7 treatment. The
hypophosphatemic action of BMP-7 was most likely due
to an increase in skeletal phosphate deposition associated
with increased mineral apposition, because increased re-
nal excretion of phosphate was not demonstrated and
preliminary studies demonstrate no effect of BMP-7 on
renal tubular phosphate transport (K.A.H and Eleanor
Lederer, unpublished data, 2000). Therefore, we favor
the interpretation that increased bone formation in the
BMP-7–treated animals led to a reduction in serum phos-
phate compared with the untreated CKD group. These
results demonstrate the contribution of renal osteodys-
trophy to hyperphosphatemia in CKD, independent of
the failure or renal excretion to maintain homeostasis,
which we generally consider paramount.
Furthermore, our studies demonstrate that a bone an-
abolic factor, BMP-7, useful in ABD and high-turnover
renal osteodystrophy [59, 26], would be therapeutic in the
metabolic syndrome with ABD. BMP-7 is an important
developmental morphogen for the skeleton, kidney, and
eye [72, 73, 74]. BMP-7 is a regulator of osteoblast dif-
ferentiation, and it has other biological functions in the
adult [75, 76, 59]. The bone morphogenetic proteins were
originally isolated from bone extracts that were capable
of inducing endochondral bone formation when placed
in mesenchymal-derived sites [77]. In vitro, BMPs have
been demonstrated to stimulate the development of os-
teoblastic cells from undifferentiated precursors [78–80,
84–86]. BMP-7 is expressed in the adult kidney-collecting
duct. It is secreted into the bloodstream and tubular fluid,
and it is excreted in the urine [83]. Renal injury results in
decreased BMP-7 production, as shown in several models
of acute and CKD [23, 24, 19]. Thus, decreases in skeletal
BMP influence could be a factor in deficient skeletal re-
modeling associated with CKD. The effects of an anabolic
factor to reverse ABD are supportive of the concept of
skeletal anabolic deficiency produced by CKD.
Induction of CKD led to a significant increase in aor-
tic calcification in the studies reported here. These re-
sults were in agreement with our previous study of VC
in this model [18]. Also in agreement were the results of
BMP-7 therapy. BMP-7 was effective in preventing the in-
crease in VC induced by CKD, but the BMP-7 effects in
the sham-operated high-fat/cholesterol-fed animals were
not significant in reducing VC. There was a strong in-
verse relationship between adjusted apposition rates and
VC in these studies, suggesting that heterotopic mineral-
ization may be related to decreased orthotopic mineral-
ization. Because high phosphate directly stimulates the
osteogenic drift in vascular smooth muscle differentia-
tion in vitro [34], hyperphosphatemia may be a mecha-
nism of direct links between skeletal mineralization rates
and vascular mineralization [35]. BMP-7, by stimulating
bone formation and correcting ABD, decreases the serum
phosphorus and VC. This conclusion is supported by
the demonstration that calcium carbonate, a phosphate
binder, decreased the serum phosphate and decreased
VC, although not completely like BMP-7 therapy. Be-
cause BMP-7 also has direct actions on the phenotype of
vascular smooth muscle cells, the greater benefit of BMP-
7 compared with sole reduction in the serum phosphate
supports the conclusion that a portion of the protective
effect of BMP-7 on VC was mediated by the stimu-
lation of bone formation and the reduction in serum
phosphorus.
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